Related Experiment Videos
Current issues in neonatal screening for cystic fibrosis and implications of the CF gene discovery
P M Farrell1, E H Mischler, N C Fost
1Department of Pediatrics, University of Wisconsin-Madison.
Insights
Widespread newborn screening for cystic fibrosis (CF) is not recommended until benefits, risks, and ethical concerns are fully addressed. Mutation analysis combined with IRT testing shows promise for future CF screening strategies.
Area of Science:
- Medical Genetics
- Neonatal Screening
- Public Health
Background:
- Cystic Fibrosis (CF) screening in newborns is under consideration.
- Current understanding of CF screening's efficacy, toxicity, and cost is incomplete.
- Ethical considerations for both CF patients and carriers require resolution.
Purpose of the Study:
- To evaluate the readiness of mass population screening for CF in newborns.
- To identify key challenges and unresolved questions in CF neonatal screening.
- To explore potential future strategies for CF screening.
Main Methods:
- Review of existing data on CF screening efficacy and toxicity.
- Analysis of logistical and financial feasibility of screening systems.
- Consideration of ethical implications for patients and carriers.
Main Results:
- Significant questions remain regarding the effectiveness, safety, and economic viability of CF neonatal screening.
- Premature implementation of mass screening is cautioned against until benefits and risks are clearly defined.
- Development of feasible testing systems and effective CF therapies are prerequisites for widespread screening.
Conclusions:
- Further research and development are necessary before implementing universal CF newborn screening.
- Mutation analysis coupled with IRT testing is a promising approach for research purposes.
- Future advancements in molecular diagnostics may offer more financially feasible primary screening methods.
Abstract:
Many questions remain regarding the efficacy, toxicity, and costs of CF neonatal screening. It would be premature, in our opinion, to implement mass population screening of newborns for CF until the benefits and risks have been fully defined, and an adequate and logistically feasible testing system developed and/or highly effective therapy for CF lung disease becomes available. In addition, the ethical issues described herein need to be resolved. This pertains not only to the CF patient but also the heterozygote carrier. These reservations notwithstanding, the discovery of the CF gene should have a favorable impact both directly and indirectly on neonatal screening for the disease. Mutation analysis coupled to IRT testing seems most attractive at this time, at least on a research basis, but primary molecular diagnostic procedures might supervene in the future, particularly if they are financially feasible.